BALTIMORE, June 2, 2011 (GLOBE NEWSWIRE) -- Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, has produced a new research update on Nuvilex, Inc. (OTCQB:NVLX), an innovative biotechnology and natural products company.
In the Goldman Opportunity Research update on the Company, analyst Rob Goldman outlines the reasoning behind the new update.
"Nuvilex has executed on a remarkable acquisition which we believe dramatically improves the valuation, prospects, and status of the Company. With this acquisition, Nuvilex leadership has re-positioned the Company in the oncology segment of the biotechnology sector which offers huge potential."
To download and view the update in its entirety, please visit .
About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap stock market research reports and weekly newsletters. For more information, visit .
A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer. To download our research, disclosures, or for more information, visit .
About Nuvilex, Inc.: Nuvilex, Inc. (OTCQB:NVLX) a Green Company believing in "Good for You, Good for the Environment" and are expanding our natural product lines and will be making important strides in the biotechnology arena (). To that end, we have acquired a treatment technology designed to combat pancreatic cancer that has completed a Phase II clinical trial. Active biotechnology advances are already aggressively ongoing at Nuvilex and new biotechnology updates will be announced shortly. Current products include Cinnergen™, Cinnechol™, and Cinnsational™ to enhance a healthy lifestyle; Talsyn™ and NumaDerm™ for cosmetic use; Citroxin™ and Oraphyte™ as antimicrobial and antinematodal agents; Reme-Flu™, Legacy Biotechnologies' flu combating regimen; and Virgin® and Infinitink®, heavy-metal-free tattoo inks.
For additional information, please visit the Company's website: .
CONTACT: Goldman Small Cap Research Rob Goldman, Analyst 410-609-7100 rob@goldmanresearch.com